Knowledge Exchange by ISID

Maximum: 1 CME cr.,
1 AutoAttendance cr.
Sign in to view your progression
Program Overview Progr...
Learning Objectives Learn...
Target Audience Targe...
References Refer...
Disclosure/Disclaimer Discl...

Activity Title: The Impact of COVID-19 on Global Infectious Diseases

Release Date: October 7, 2020

Estimated Time to Complete Activity: 70 minutes

Statement of Need:

COVID-19 may have complex short- and long-term effects on global infectious disease priorities. With the world’s attention and resources focused towards COVID-19 prevention and response efforts, we are at risk of major infectious diseases making a comeback. As observed during previous crises, the indirect morbidity and mortality effects of the ongoing COVID-19 pandemic may be as important as the direct effects of the pandemic itself. There are widespread disruptions to HIV, TB and malaria service delivery programs globally with shortages in medical supplies, treatments and diagnostics. Existing programs have been hit by lockdowns, changing funding priorities and re-allocation of staff and resources. It is estimated that the disruption of routine childhood immunization services across the globe puts at least 80 million children under one at risk of vaccine-preventable diseases such as measles, mumps, rubella, polio, yellow fever, typhoid, cholera and tetanus. On the other hand, emphasis on infection prevention measures such as hand hygiene and social distancing could reduce the occurrence of community and healthcare associated infectious diseases, providing an opportunity to harness improved practices, behavior changes and attitude modifications relevant to the management of many infections. The full impact of COVID-19 on respiratory diseases and the influenza season remains unknown. Disruptions in disease surveillance and reporting further add to the complexity of understanding the true impact of COVID-19 on communicable diseases.

Prof. Lulu Bravo
Professor Emeritus University of the Philippines, Manila

Prof. François Venter
Director of Ezintsha, Faculty of Health Sciences, University of the Witwatersrand

Technical Requirements

This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers. For interactive content a broadband connection is required. For CME/CE activities featuring audio you need a sound card and speakers.

Our activities may require JavaScript to be enabled on your computer. If you are having difficulty viewing pop-up windows, click here for instructions on enabling JavaScript.

Contact Information

If you have questions about this CME activity, please contact The International Society for Infectious Diseases at

For technical support issues, please contact Multilearning at

Upon completion of this module, participants should be able to:

  • Discuss the wider impact of COVID-19 on global infectious disease priorities
  • Understand the urgency of tackling the COVID-19 pandemic while simultaneously dealing with  existing priorities
  • Restate the need to gather knowledge and evidence to rapidly shape and inform coordinated strategies at the individual, health-care and policy levels to reduce the potential longer-term impact.

The target audience for this module is physicians, nurses, public health officials, researchers, immunization officers, and other health professionals.

WHO and UNICEF warn of a decline in vaccinations during COVID-19:

Abbas K, Procter SR, van Zandvoort K, et al; LSHTM CMMID COVID-19 Working Group. Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit-risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. Lancet Glob Health. 2020 Oct;8(10):e1264-e1272. doi: 10.1016/S2214-109X(20)30308-9.

Bramer CA, Kimmins LM, Swanson R, et al. Decline in Child Vaccination Coverage During the COVID-19 Pandemic — Michigan Care Improvement Registry, May 2016–May 2020. MMWR Morb Mortal Wkly Rep 2020;69:630–631. DOI:


The Global Fund: The Impact of COVID-19 on HIV, TB and Malaria Services and Systems for Health: A Snapshot from 502 Health Facilities across Africa and Asia.

Togun T, Kampmann B, Stoker NG, Lipman M. Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. Ann Clin Microbiol Antimicrob. 2020 May 23;19(1):21. doi: 10.1186/s12941-020-00363-1.

McQuaid CF, McCreesh N, Read JM, Sumner T; CMMID COVID-19 Working Group, Houben RMGJ, White RG, Harris RC. The potential impact of COVID-19-related disruption on tuberculosis burden. Eur Respir J. 2020 Aug 13;56(2):2001718. doi: 10.1183/13993003.01718-2020.

Bhatia V, Mandal PP, Satyanarayana S, et al. Mitigating the impact of the COVID-19 pandemic on progress towards ending tuberculosis in the WHO South-East Asia Region. WHO South East Asia J Public Health. 2020 Sep;9(2):95-99. doi: 10.4103/2224-3151.294300.;year=2020;volume=9;issue=2;spage=95;epage=99;aulast=Bhatia

Disclosure Policy

In accordance with the EACCME Standards for Commercial Support, the International Society for Infectious Diseases (ISID) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. ISID  resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all our educational programs. Furthermore, ISID seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. ISID is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures:

The planners, reviewers, editors, staff, or other members at the International Society for Infectious Diseases who control content have no relevant financial relationships to disclose. 

ISID Knowledge Exchange and E-Learning Platform Organizing Committee members are listed here along with Committee members’ disclosure forms. 

Faculty Disclosures:

Professor Lulu C. Bravo has no actual or potential conflict of interest in relation to this program/presentation

Professor Francois Venter's disclosures:

Grants/Research Support:
Funding from the Bill and Melinda Gates Foundation, SA Medical Research Council, National Institutes for Health, AIDS Funds, Unitaid, Foundation for Innovative New Diagnostics, the Children’s Investment Fund Foundation, USAID. Drug donations from ViiV Healthcare, Merck and Gilead (for investigator-led clinical studies).

  • Investigator led studies for Merck and ViiV
  • Commercial drug studies for Merck
  • Evaluations of diagnostic devices for various biotech companies

Honoraria/Consultation fees:
Gilead, ViiV, Mylan, Merck, Adcock-Ingram, Aspen, Abbott, Roche, J&J, Virology Education

Moderator Disclosures:

Professor Alison Holmes
Grants/Research Support: Co-Supervisor (with the Department of Chemistry) of a PhD fellowship funded through a collaborative programme involving industry partnerships. Industry partner: Shionogi (£15,000 per annum to Imperial College for a PhD studentship)

Spouse/Partner: On the GSK Vaccine Scientific Advisory Board

Dr. Afreenish Amir has no actual or potential conflict of interest in relation to this program/presentation.

Prof Paul Anantharajah Tambyah: 
Grants/Research Support: Roche, Arcturus, Johnson and Johnson

Disclosure of Unlabeled Use

The International Society for Infectious Diseases  requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ISID does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.


The International Society for Infectious Diseases presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The International Society for Infectious Diseases, and the former commercial supporter assume no liability for the information herein.

Copyright Information

Copyright © 2021 by the International Society for Infectious Diseases. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

•  The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

•  Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without the International Society for Infectious Diseases' prior written permission.

Privacy Policy

The International Society for Infectious Diseases protects the privacy of personal and other information regarding participants and educational collaborators. The International Society for Infectious Diseases will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The International Society for Infectious Diseases maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding the International Society for Infectious Diseases Privacy Policy and ISID’s Knowledge Exchange and E-Learning Platform Privacy Policy can be viewed at and

ISID WEBINAR SERIES: The Impact of COVID-19 on Global Infectious Diseases

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies